Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Acute Normovolemic Hemodilution in Bone Cancer Surgery

The Effect of Acute Normovolemic Hemodilution on Requirement of Allogeneic Red Blood Cell in Patients Undergoing Bone Cancer Surgery

Malignant bone tumors often lead to skeletal complications, known as skeletal related events (SRE). These complications mainly include pathological fractures, severe pain, and spinal cord compression. Typically, SRE reduces overall survival rates and is associated with loss of mobility and social functioning, decreased quality of life, and significantly increased healthcare costs. Surgical resection is an important means of treating malignant bone tumors. The main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for malignant bone tumors often requires extensive exploration, osteotomy, and prosthetic reconstruction. The surgery involves significant trauma and excessive bleeding from the wound. Therefore, there is a significant risk of perioperative blood loss and transfusion during surgery for malignant bone tumors. However, blood transfusion also brings transfusion related risks to patients, increases the incidence of postoperative complications, and increases the healthcare burden on patients and society. Acute normovolemic hemodilution (ANH) may help reduce allogeneic red blood cell transfusion. However, There is a lack of high-quality evidence to support the use of ANH in bone cancer surgery.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Malignant bone tumors often lead to skeletal complications, known as skeletal related events (SRE). These complications mainly include pathological fractures, severe pain, and spinal cord compression. Typically, SRE reduces overall survival rates and is associated with loss of mobility and social functioning, decreased quality of life, and significantly increased healthcare costs. Surgical resection is an important means of treating malignant bone tumors. The main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for bone cancer often requires extensive exploration, osteotomy, and prosthetic reconstruction. The surgery involves significant trauma and excessive bleeding from the wound. Therefore, there is a significant risk of perioperative blood loss and transfusion during surgery for malignant bone tumors. However, blood transfusion also brings transfusion related risks to patients, increases the incidence of postoperative complications, and increases the healthcare burden on patients and society. Therefore, it is particularly important to develop a perioperative blood management (PBM) plan for these patients. Acute normovolemic hemodilution (ANH) may help reduce allogeneic red blood cell transfusion. However, There is a lack of high-quality evidence to support the use of ANH in bone cancer surgery.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

420

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Beijing, Kina, 100034
        • Peking University First Hospital
      • Beijing, Kina, 100035
        • Beijing Jishuitan Hospital
      • Shanghai, Kina, 200032
        • Fudan University Shanghai Cancer Center
      • Shanghai, Kina, 200080
        • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
      • Shanghai, Kina, 200233
        • Sixth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine
      • Sichuan, Kina, 610041
        • West China Hospital, Sichuan University
      • Wuhan, Kina, 430022
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310000
        • The Second Affiliated Hospital of Zhejiang University anesthesiology department
        • Ledende efterforsker:
          • Min Yan, Doctor
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. age 18 more than years;
  2. undergoing elective bone cancer resection surgery;
  3. preoperative hemoglobin ≥12 g/dL;

Exclusion Criteria:

  1. anticipated tourniquet use, endovascular balloon occlusion of the aorta or biopsy only;
  2. weight < 50Kg or > 100Kg;
  3. international normalized ratio (INR) >1.5 or platelet count <100 × 10^9/L;
  4. cardiopulmonary insufficiency;
  5. hepatic and renal dysfunction;
  6. active infectious disease;
  7. allergy to colloid solution;
  8. pregnancy;
  9. declined participation in the study or declined blood transfusion

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Control group

Except for not undergoing ANH, other care managements are the same as the experimental group

Eksperimentel: ANH group

Patients in the ANH group had whole blood withdrawn after induction of anesthesia. Meanwhile, patients receive colloid solution according to the volume of blood withdrawn.

The whole blood is withdrawn after induction of anesthesia. Blood is withdrawn from a large-bore catheter and stored in blood bags. Meanwhile, patients receive colloid solution according to the volume of blood withdrawn.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Perioperative red blood cell transfusion rate
Tidsramme: hospital discharge, an average of 10 days

The number of patients receiving RBCs transfusion from the start of surgery to hospital discharge.

hospital discharge, an average of 10 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The rate of perioperative transfusion of allogeneic blood products
Tidsramme: hospital discharge, an average of 10 days

This includes blood products such as plasma and platelets, erythrocytes

hospital discharge, an average of 10 days
Wound drainage volume
Tidsramme: hospital discharge, an average of 10 days

Accumulated amount of wound drainage after surgery

hospital discharge, an average of 10 days
Unplanned re-operation
Tidsramme: hospital discharge, an average of 10 days

Unplanned re-operation due to bleeding, infection or other reasons

hospital discharge, an average of 10 days
Perioperative hemoglobin concentration
Tidsramme: hospital discharge, an average of 10 days

hemoglobin concentration during hospitalization

hospital discharge, an average of 10 days
The coagulation function tests during the perioperative period
Tidsramme: hospital discharge, an average of 10 days

This includes thromboelastography result

hospital discharge, an average of 10 days
Complication
Tidsramme: hospital discharge, an average of 10 days

embolic events, pulmonary complications, infection, acute kidney injury, death. Diagnose according to radiologic examination, sign and symptom

hospital discharge, an average of 10 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. oktober 2026

Primær færdiggørelse (Anslået)

1. oktober 2028

Studieafslutning (Anslået)

1. december 2028

Datoer for studieregistrering

Først indsendt

22. juni 2026

Først indsendt, der opfyldte QC-kriterier

22. juni 2026

Først opslået (Faktiske)

25. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. september 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2026 0947

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .